Accordingly, clinical trials—only in RA—with TNF blockers (16) and the Il-6 receptor blockade (84), have confirmed the impact of pro-inflammatory cytokines on osteoclastogenesis as they can retard or arrest the occurrence of bone erosion. The gene discussed is TNF; the disease is rheumatoid arthritis.